Fore Biotherapeutics
PrivateLast Round
Series D
Extension
May 22, 2025
Est. Valuation
$75M
Total Funding Raised
$188.5M
Momentum Score
25 /100
Company Overview
Fore Biotherapeutics is a clinical-stage precision oncology company developing treatments for patients with rare, unaddressed tumor mutations. The company utilizes its proprietary functional genomics platform, Foresight, to screen for mutations in cancer-driving genes and identify existing compounds that could be effective therapies. This strategy focuses on in-licensing clinical-stage assets and matching them to hyper-targeted patient populations to accelerate development. The company's lead program is plixorafenib, a next-generation BRAF inhibitor designed to treat a wide range of BRAF-mutated cancers. Originally founded in Israel as NovellusDx, a diagnostics company, it rebranded in 2021 and pivoted to therapeutics, establishing its global headquarters in Philadelphia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Fore Biotherapeutics Comps
Public and private peers based on sector, stage, and business model.
Fore Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | May 22, 2025 | ||||
| Series D | Aug 23, 2023 | ||||
| Series C | Sep 21, 2020 | ||||
| Series B | Apr 30, 2018 | ||||
| Series A | Jun 22, 2016 | ||||
VC Round | Dec 24, 2015 |
Fore Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 3B FUTURE Health Fund | Series D, Series D Extension |
| OrbiMed | Series D, Series B, Series C, Series A, Series D Extension |
| Novartis Venture Fund | Series D, Series C, Series D Extension |
| HBM Healthcare Investments | Series D, Series C, Series D Extension |
| Wellington Management | Series D, Series C, Series D Extension |
| Takeda Ventures | Series C |
| SR One | Series C, Series D, Series D Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 15, 2025
Preparing for registration and launch of plixorafenib for BRAF mutations.
- May 22, 2025
$38M raised in Series D Extension round.
Fore Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Fore Biotherapeutics's valuation, stock price, and market status.
